PARIS--(BUSINESS WIRE)--Regulatory News: Cellectis SA (Paris:ALCLS) (Alternext: ALCLS.PA) announces that it has entered into an exclusive license agreement with The Ohio State University, through the Ohio State Innovation Foundation, to develop and commercialize chimeric antigen receptor (CAR) technology targeting multiple myeloma cells. The CAR technology licensed to Cellectis is related to CS1, an antigen that is over-expressed in multiple myeloma cells. Cellectis intends to pursue the development of a CS1 CAR T-cell program for this targeted indication.
Help employers find you! Check out all the jobs and post your resume.
